| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1053/SONC.2002.35524 |
| P698 | PubMed publication ID | 12422304 |
| P2093 | author name string | Jean-Louis Misset | |
| Jim Cassidy | |||
| P433 | issue | 5 Suppl 15 | |
| P921 | main subject | oxaliplatin | Q422327 |
| P304 | page(s) | 11-20 | |
| P577 | publication date | 2002-10-01 | |
| P1433 | published in | Seminars in Oncology | Q14330412 |
| P1476 | title | Oxaliplatin-related side effects: characteristics and management | |
| P478 | volume | 29 |
| Q86521729 | A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer |
| Q34321665 | A novel behavioral assay for measuring cold sensation in mice |
| Q41912667 | A pH responsive complexation-based drug delivery system for oxaliplatin |
| Q33373035 | A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression |
| Q33400418 | A rare case of acute kidney injury associated with autoimmune hemolytic anemia and thrombocytopenia after long-term usage of oxaliplatin |
| Q35906940 | A review of oxaliplatin and its clinical use in colorectal cancer |
| Q58119442 | ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells |
| Q37955698 | Acute pain associated with oxaliplatin infusion: case report and literature review. |
| Q33397057 | Adverse event profiles of platinum agents: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations |
| Q41862568 | Analgesic Effects of Bee Venom Derived Phospholipase A(2) in a Mouse Model of Oxaliplatin-Induced Neuropathic Pain |
| Q36174729 | Aqueous extract of Lithospermi radix attenuates oxaliplatin-induced neurotoxicity in both in vitro and in vivo models |
| Q37111987 | Assessment of nerve excitability in toxic and metabolic neuropathies |
| Q84593041 | Cellular uptake and cytoplasm / DNA distribution of cisplatin and oxaliplatin and their liposomal formulation in human colorectal cancer cell HCT116 |
| Q37118923 | Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer |
| Q42022293 | Cetuximab-induced hypomagnesaemia aggravates peripheral sensory neurotoxicity caused by oxaliplatin. |
| Q50103900 | Changes in upper extremity function, ADL, and HRQoL in colorectal cancer patients after the first chemotherapy cycle with oxaliplatin: a prospective single-center observational study. |
| Q46484458 | Combined systemic chronotherapy and hepatic artery infusion for the treatment of metastatic colorectal cancer confined to the liver |
| Q37008334 | Conus vexillum venom induces oxidative stress in Ehrlich's ascites carcinoma cells: an insight into the mechanism of induction |
| Q47142492 | Curcumin activates DNA repair pathway in bone marrow to improve carboplatin-induced myelosuppression. |
| Q48151951 | Differential resistance to platinum-based drugs and 5-fluorouracil in p22phox-overexpressing oral squamous cell carcinoma: Implications of alternative treatment strategies. |
| Q33873552 | Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity |
| Q45257462 | Dysphonia as an unusual toxic event of oxaliplatin-based chemotherapy |
| Q50797877 | Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. |
| Q35103028 | Efficacy of goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colorectal cancer |
| Q38684985 | Emotional Responses to Persistent Chemotherapy-induced Peripheral Neuropathy Experienced by Patients with Colorectal Cancer in Japan |
| Q91668842 | Evaluation of oxaliplatin-induced pulmonary toxicity in rats |
| Q46717319 | First-line treatment of advanced gastric cancer and hepatic dysfunction with oxaliplatin, 5-fluorouracil and cetuximab |
| Q35629061 | First-line treatment strategies to improve survival in patients with advanced colorectal cancer |
| Q40189576 | Granulomatous lung disease requiring mechanical ventilation induced by a single application of oxaliplatin-based chemotherapy for colorectal cancer: a case report. |
| Q33257302 | Hemolytic uremic syndrome following the infusion of oxaliplatin: case report |
| Q55514992 | High-intensity interval training and hyperoxia during chemotherapy: A case report about the feasibility, safety and physical functioning in a colorectal cancer patient. |
| Q41125323 | Houttuynia cordata Thunb reverses oxaliplatin-induced neuropathic pain in rat by regulating Th17/Treg balance |
| Q58729712 | Immunogenic Effect of Hyperthermia on Enhancing Radiotherapeutic Efficacy |
| Q35772998 | L type Ca²+ channel blockers prevent oxaliplatin-induced cold hyperalgesia and TRPM8 overexpression in rats |
| Q36129089 | Laser acupuncture attenuates oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancer: a pilot prospective cohort study |
| Q27026129 | Management of locally advanced and metastatic colon cancer in elderly patients |
| Q30446860 | Membrane transporters as mediators of Cisplatin effects and side effects |
| Q37938364 | Membrane-active host defense peptides--challenges and perspectives for the development of novel anticancer drugs |
| Q36893806 | Metastatic colorectal cancer-past, progress and future |
| Q36159222 | Molecular mechanism of adenomatous polyposis coli-induced blockade of base excision repair pathway in colorectal carcinogenesis |
| Q35758048 | Molecular mechanisms of resistance and toxicity associated with platinating agents |
| Q34338695 | Nanocarriers for delivery of platinum anticancer drugs. |
| Q89910592 | Neuropathy experienced by colorectal cancer patients receiving oxaliplatin: A qualitative study to validate the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity scale |
| Q35692169 | Neurotoxicity caused by the treatment with platinum analogues |
| Q40308106 | Organizing pneumonia associated with oxaliplatin-combined chemotherapy: a case report |
| Q38540596 | Oxaliplatin for the treatment of ovarian cancer. |
| Q38789716 | Oxaliplatin immunohybrid nanoparticles in vitro synergistic suppression evaluation in treatment of colorectal cancer |
| Q36788436 | Oxaliplatin in the treatment of colorectal cancer |
| Q36740632 | Oxaliplatin-DNA adduct formation in white blood cells of cancer patients |
| Q28546867 | Oxaliplatin-Induced Peripheral Neuropathy via TRPA1 Stimulation in Mice Dorsal Root Ganglion Is Correlated with Aluminum Accumulation |
| Q41841259 | Oxaliplatin-Induced Tonic-Clonic Seizures |
| Q34394155 | Oxaliplatin-Related Ocular Toxicity |
| Q33391330 | Oxaliplatin-induced acute thrombocytopenia. |
| Q55605577 | Oxaliplatin-induced bronchiolitis obliterans organizing pneumonia following hyperthermic intraperitoneal chemotherapy. |
| Q37983953 | Oxaliplatin-induced hepatocellular injury and ototoxicity: a review of the literature and report of unusual side effects of a commonly used chemotherapeutic agent |
| Q43278321 | Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. |
| Q35214568 | Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer |
| Q34611822 | Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study |
| Q33361500 | Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. |
| Q46641350 | Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer |
| Q46990345 | Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study). |
| Q54409428 | Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity |
| Q36111392 | Preparation and In Vivo Evaluation of Dichloro(1,2-Diaminocyclohexane)platinum(II)-Loaded Core Cross-Linked Polymer Micelles |
| Q39657494 | Prevention of oxaliplatin‐induced mechanical allodynia and neurodegeneration by neurotropin in the rat model |
| Q43066432 | Preventive Effects of Bee Venom Derived Phospholipase A₂ on Oxaliplatin-Induced Neuropathic Pain in Mice |
| Q52562413 | Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer. |
| Q89338392 | Rechallenge with oxaliplatin and peripheral neuropathy in colorectal cancer patients |
| Q27021105 | Review of systemic therapies for locally advanced and metastatic rectal cancer |
| Q58798015 | Risk factors for oxaliplatin-induced vascular pain in patients with colorectal cancer and comparison of the efficacy of preventive methods |
| Q38474594 | Role of transporters in the distribution of platinum-based drugs |
| Q37673380 | Sarcoidosis associated with oxaliplatin-based chemotherapy for colorectal cancer |
| Q36545850 | Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication |
| Q24650885 | Studies on anticancer activities of antimicrobial peptides |
| Q26830695 | Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management |
| Q47326759 | The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen |
| Q38888345 | The Role of Transporters in the Toxicity of Chemotherapeutic Drugs: Focus on Transporters for Organic Cations |
| Q88388028 | The Suppressive Effects of Cinnamomi Cortex and Its Phytocompound Coumarin on Oxaliplatin-Induced Neuropathic Cold Allodynia in Rats |
| Q36072532 | The clinical analysis of acute pancreatitis in colorectal cancer patients undergoing chemotherapy after operation |
| Q82462847 | The current state of the drugs for the treatment of peripheral neuropathy induced by anticancer drugs |
| Q64062503 | Three different polymorphisms of the DPYD gene associated with severe toxicity following administration of 5-FU: a case report |
| Q33357351 | Toxicities of the platinum antineoplastic agents |
| Q40299140 | Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. |
| Q35598162 | Tumor microenvironment in focus: LA-ICP-MS bioimaging of a preclinical tumor model upon treatment with platinum(IV)-based anticancer agents. |
| Q36694455 | UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer |
| Q89907646 | lncRNA MALAT1 modulates oxaliplatin resistance of gastric cancer via sponging miR-22-3p |
Search more.